Scarica l'app Stockscreener
13.48
28.26%
2.97
Pre-mercato:
13.52
0.04
+0.30%
Evolus Inc Borsa (EOLS) Ultime notizie
Stifel maintains Buy on Evolus, price target steady at $25 - MSN
Evolus projects robust 2025 growth with upcoming product launches - MSN
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance - BioSpace
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates - Benzinga
Evolus Shares Surge 34% on Record Q4 Revenue and FDA Approval Ex - GuruFocus.com
Evolus (NASDAQ:EOLS) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why - MSN
Evolus (NASDAQ:EOLS) Shares Gap UpTime to Buy? - MarketBeat
Evolus announces Q4 preliminary unaudited net revenue of $79M - MSN
Evolus shares surge on strong Q4 results and upbeat 2025 outlook - MSN
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
Evolus Shares Rise on Jump in Revenue - MarketWatch
Evolus, Inc. Provides Financial Guidance for the Full Year of 2025 -January 21, 2025 at 08:00 am EST - Marketscreener.com
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Trend Tracker for (EOLS) - Stock Traders Daily
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25 (NASDAQ:EOLS) - Seeking Alpha
Evolus (NASDAQ:EOLS) Hits New 1-Year LowHere's Why - MarketBeat
Possible Bearish Signals With Evolus Insiders Disposing Stock - Simply Wall St
Evolus stock touches 52-week low at $10.23 amid market shifts - Investing.com Nigeria
Evolus (NASDAQ:EOLS) Sets New 52-Week LowHere's What Happened - MarketBeat
EVOLUS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased E - PR Newswire
(EOLS) Technical Data - Stock Traders Daily
Barclays PLC Grows Stake in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Inc (EOLS) Trading Down 3.61% on Dec 27 - GuruFocus.com
Evolus CFO Sandra Beaver sells shares worth $17,211 By Investing.com - Investing.com Australia
Evolus chief medical officer sells shares worth $24,438 By Investing.com - Investing.com Australia
Evolus chief medical officer sells shares worth $24,438 - Investing.com India
Evolus CFO Sandra Beaver sells shares worth $17,211 - Investing.com India
Evolus, Inc. (NASDAQ:EOLS) CFO Sells $17,208.10 in Stock - MarketBeat
Evolus, Inc. (NASDAQ:EOLS) Insider Sells $24,434.20 in Stock - MarketBeat
Evolus CEO David Moatazedi sells $113,966 in stock By Investing.com - Investing.com Nigeria
Evolus CEO David Moatazedi sells $113,966 in stock - Investing.com
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by State Street Corp - MarketBeat
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability - Yahoo Finance
Lord Abbett & CO. LLC Acquires 188,685 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Stock Options Galore! Discover Evolus’ Latest Move - Jomfruland.net
(EOLS) On The My Stocks Page - Stock Traders Daily
Evolus Expands Team with Strategic Equity Incentives Package for 20 New Hires - StockTitan
Evolus's SWOT analysis: aesthetics firm's stock poised for growth By Investing.com - Investing.com South Africa
Evolus's SWOT analysis: aesthetics firm's stock poised for growth - Investing.com
2.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):